Category: Research
-
![Revive Therapeutics (RVV.C) finds multiple research options moving forward]()
Revive Therapeutics (RVV.C) finds multiple research options moving forward
In Canada, if you look backwards over the timeline, you’ll often find public companies have been other things back in the day. Risen, fallen, tapped out, rolled back, reemerged as a whole new thing. Sometimes this happens several times before a business model catches. Revive Therapeutics (RVV.C) is that rare Canadian smallcap that, while it…
-
![Cannabis memory lane: Who’s sticking it out, who’s dead and dying]()
Cannabis memory lane: Who’s sticking it out, who’s dead and dying
I was feeling every ounce of my chest cold, the thing everyone apparently has, the one that’s going around, the one that’s not covid but who could tell. I was also standing on a stage at the Richmond Chamber of Commerce awards gala, blinking at stage lights and peaking over the shoulders of some very…
-
![Pubco cocaine is here: What does it mean, who’s in, and who’s real?]()
Pubco cocaine is here: What does it mean, who’s in, and who’s real?
I recently listened to a podcast episode of Search Engine with PJ Vogt, and I REALLY got into it. The episode was titled, “Why are drug dealers putting fentanyl in everything?” I’d asked myself the same question many times – why kill your customers? I’d recommend you go listen because the answer is a lot…
-
![Tipping the Scale: Navigating the Turbulent Waters of the Canadian Legal Cannabis Market]()
Tipping the Scale: Navigating the Turbulent Waters of the Canadian Legal Cannabis Market
The legal cannabis industry in Canada, still in its infancy nearly five years post-legalization, is traversing a tumultuous terrain. As the initial euphoria fades, the market is grappling with mounting challenges. These include the continuous race to the bottom with pot prices, the persistent prevalence of the illicit market, and the looming uncertainties in the…
-
![Canntab Therapeutics (PILL.C): a pressing investment opportunity – Today’s Idea]()
Canntab Therapeutics (PILL.C): a pressing investment opportunity – Today’s Idea
Canntab Therapeutics (PILL.C) has been around the block and then some. The Ontario-based pharmaceutical answer to medicinal cannabis, has pioneered a patented process to turn CBD, THC and terpene and other cannabinoid distillates into hard-pressed pills that reliably deliver accurately measured dosages with optimal bioavailability. The company’s instant release and extended-release formulations round out a…
-
Revive Therapeutics (RVV.C) files for FDA Orphan Drug Designation for psilocybin in traumatic brain injury
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function after TBI lessening disability”.
-
![Pure Extracts (PULL.C) to enter U.S. market through JV in Michigan]()
Pure Extracts (PULL.C) to enter U.S. market through JV in Michigan
If the LOI becomes a binding contract, Pure Extracts will contribute “a mix of equipment and cash to the venture”, which will allow the partners to rapidly scale-up to meet the rising demand for recreation cannabis concentrates and edibles throughout Michigan.
-
![As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat]()
As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat
News this week that Canntab Therapeutics (PILL.C) received an Australian patent for their hard-pressed cannabis pill tech, to match those received earlier in North America, didn’t launch the stock into space. That’s understandable, to be honest, as North American investors have taken an eye off the island continent and its slow roll to weed legalization…
-
![Revive Therapeutics (RVV.C) CEO Michael Frank likes the stock, buys the dip]()
Revive Therapeutics (RVV.C) CEO Michael Frank likes the stock, buys the dip
+135k shares in a downturn, my man The psychedelics sector is down bad this week. Just look at the psychedelics ETF PSYK.NE. It’s not an alarm or anything, things have been running pretty nicely the past couple of quarters and it was probably time for a correction. Any time a sector emerges this quickly there…
-
![Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)]()
Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)
Cannabis hard tablet IP holder Canntab Therapeutics (PILL.C) continues to send product to market, announcing Wednesday they’ve fulfilled 80% of their contract with Medipharm Labs (LABS.T), bringing in another half million dollars in revenue toward the $1.3 million deal announced last June. Orders under the agreement are a mix of Canntab’s proprietary instant release tablets…
